Hubei Guangji Pharmaceutical Co., Ltd. (SHE:000952)
China · Delayed Price · Currency is CNY 6.48
+0.06 (0.93%)
Sep 14, 2026, 3:04 PM CST
SHE:000952 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,226 | 2,438 | 2,162 | 2,828 | 2,711 | 2,694 | |
Market Cap Growth | -3.89% | 12.74% | -23.55% | 4.31% | 0.66% | 5.00% |
Enterprise Value | 3,246 | 2,919 | 3,232 | 3,737 | 2,862 | 2,743 |
Last Close Price | 6.42 | 7.03 | 6.18 | 7.99 | 7.66 | 7.77 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | 53.87 | 24.46 |
Forward PE | - | 5.34 | 5.34 | 5.34 | 5.34 | 5.34 |
PS Ratio | 3.42 | 3.91 | 3.39 | 3.83 | 3.40 | 3.43 |
PB Ratio | 3.93 | 3.89 | 2.01 | 2.03 | 1.82 | 1.86 |
P/TBV Ratio | 5.60 | 5.42 | 2.62 | 2.47 | 2.01 | 2.06 |
P/FCF Ratio | 35.75 | 98.34 | - | - | - | - |
P/OCF Ratio | 28.22 | 40.34 | 3299.14 | - | 60.15 | 35.48 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.98 | 4.68 | 5.06 | 5.07 | 3.59 | 3.49 |
EV/EBITDA Ratio | 189.73 | 459.63 | - | 155.43 | 19.27 | 15.40 |
EV/EBIT Ratio | - | - | - | - | 55.99 | 31.43 |
EV/FCF Ratio | 52.12 | 117.76 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 2.33 | 1.53 | 0.81 | 0.63 | 0.44 | 0.26 |
Debt / EBITDA Ratio | 74.06 | 137.62 | - | 34.60 | 4.43 | 2.12 |
Debt / FCF Ratio | 21.14 | 38.77 | - | - | - | - |
Net Debt / Equity Ratio | 1.86 | 1.09 | 0.53 | 0.33 | 0.16 | 0.06 |
Net Debt / EBITDA Ratio | 72.96 | 107.47 | -10.71 | 19.07 | 1.55 | 0.48 |
Net Debt / FCF Ratio | 16.89 | 27.53 | -3.67 | -0.64 | -1.45 | -4.10 |
Asset Turnover | 0.25 | 0.24 | 0.22 | 0.27 | 0.35 | 0.39 |
Inventory Turnover | 1.72 | 1.67 | 1.69 | 2.11 | 2.64 | 2.97 |
Quick Ratio | 0.32 | 0.39 | 0.58 | 0.83 | 1.11 | 0.91 |
Current Ratio | 0.53 | 0.61 | 0.99 | 1.25 | 1.54 | 1.31 |
Return on Equity (ROE) | -53.75% | -51.55% | -25.53% | -10.57% | 3.24% | 7.51% |
Return on Assets (ROA) | -3.22% | -3.75% | -4.66% | -2.15% | 1.41% | 2.71% |
Return on Invested Capital (ROIC) | -10.21% | -10.39% | -12.43% | -5.30% | 2.49% | 5.13% |
Return on Capital Employed (ROCE) | -18.90% | -16.50% | -11.60% | -4.40% | 2.80% | 5.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -17.38% | -16.59% | -13.66% | -4.96% | 1.86% | 4.09% |
FCF Yield | 2.80% | 1.02% | -7.13% | -25.28% | -5.85% | -0.77% |
Dividend Yield | - | - | - | - | - | 0.77% |
Payout Ratio | - | - | - | - | 79.95% | 32.38% |
Buyback Yield / Dilution | 0.91% | 1.01% | 0.60% | -0.36% | -2.54% | -2.85% |
Total Shareholder Return | 0.91% | 1.01% | 0.60% | -0.36% | -2.54% | -2.08% |